| abstract |
The present disclosure relates generally to compounds useful for treating conditions associated with checkpoint kinase (CHK), specifically the CHK-1 enzyme. Specifically, the present invention discloses compounds of formula (IA) that exhibit inhibitory activity against the CHK-1 enzyme. Methods of treating conditions associated with excessive activity of the CHK-1 enzyme with such compounds are disclosed. Their uses, pharmaceutical compositions, kits and methods of synthesis are also disclosed. |